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ABSTRACT
Background. Esophagectomy is a technically demanding
procedure associated with high levels of morbidity. Anas-
tomotic leak (AL) is a common complication with
potentially major ramifications for patients. It has also been
associated with poorer long-term overall survival (OS) and
disease recurrence.
Objective. The aim of this study was to determine whether
AL contributes to poor OS and recurrence-free survival
(RFS) for patients with esophageal cancer.
Methods. Consecutive patients undergoing a two-stage,
two-field transthoracic esophagectomy from a single high-
volume unit between 1997 and 2016 were evaluated.
Clinicopathologic characteristics, along with oncological
and postoperative outcomes, were stratified by no AL
versus non-severe leak (NSL) versus severe esophageal AL
(SEAL). SEAL was defined as ALs associated with Cla-
vien–Dindo grade III/IV complications.
Results. This study included 1063 patients, of whom 8%
(87/1063) developed AL; 45% of those who developed AL
were SEALs (39/87). SEAL was associated with a pro-
longed critical care stay (median 8 vs. 3 vs. 2 days;
p\ 0.001) and prolonged hospital stay (median 43 vs. 27
vs. 15 days; p\ 0.001) compared with NSL or no AL.
There were no significant differences in number of lymph
nodes harvested and rates of R1 resection between groups.
OS and RFS were not affected by either NSL or SEAL, and
Cox multivariate regression showed NSL and SEAL were
not independently associated with OS and RFS. Sensitivity
analysis in patients receiving neoadjuvant therapy followed
by esophagectomy demonstrated similar findings.
Conclusion. These results demonstrate that AL leads to
prolonged critical care and in-hospital length of stay;
however, contrary to previous reports, our results do not
compromise long-term outcomes and are unlikely to have a
detrimental oncological impact.
Esophagectomy remains a key component of treatment
for patients with potentially curable esophageal cancer.
While mortality levels from the procedure have fallen
dramatically over the last 30 years, esophagectomy is still
associated with high levels of morbidity.1–3 Anastomotic
leak (AL) is a commonly seen complication that has his-
torically been associated with high mortality rates.4 The
Esophagectomy Complications Consensus Group (ECCG)
defined AL as a full-thickness defect involving the
esophagus, anastomosis, staple line or conduit, irrespective
of the presentation or method of identification.5 The clas-
sification further divided leaks into the management
strategy employed: type I, those that require no change in
treatment; type II, leaks that require intervention, but not
surgery; and type III, leaks that require surgical
intervention.
The incidence of AL has been reported at between 3 and
30%.6,7 This can result in a prolonged hospital stay, a need
for reoperation, anastomotic stricturing that requires repe-
ated dilations, and potentially poorer long-term survival.8,9
A French multicenter study, which defined severe
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esophageal leaks (SEALs) as those that equated to a grade
III/IV Clavien–Dindo complication, demonstrated poor
long-term prognosis in patients who developed SEAL
following esophagectomy.9 This study was limited by
variations in oncological and surgical pathways and
included a mixture of high- and low-volume units. Fur-
thermore, this study did not report on recurrence-free
survival (RFS).
Despite the above study, the impact of AL is unclear,
with conflicting evidence, and the majority of the published
literature are limited by small series.4,9–12 The aim of this
study was to evaluate outcomes from a single high-volume
center and to determine whether AL impacts on oncolog-
ical and postoperative outcomes as well as long-term
overall survival (OS) and RFS.
METHODS
Patient Population
Consecutive patients from the Northern Oesophagogas-
tric Unit, Newcastle upon Tyne, treated for
adenocarcinoma or squamous cell carcinoma (SCC) of the
esophagus or gastroesophageal junction between January
1997 and December 2016 were included. All patients were
discussed at a multidisciplinary meeting and subsequently
received neoadjuvant chemo(radio)therapy followed by
transthoracic esophagectomy (Ivor Lewis). Patients were
identified from a contemporaneously maintained database.
Pretreatment Staging
All patients were staged according to standardized
protocols, which included endoscopy with biopsy, endo-
scopic ultrasonography, external ultrasonography of the
neck (if required), and a thoracoabdominal computed
tomography (CT) scan. A positron emission tomography
(CT) scan is used in patients being considered for radical
(curative) treatment. In patients with histology proven,
locally advanced resectable malignancy without metastases
(cT1N ? or cT3N0-3) or tumors of questionable
resectability (cT4), neoadjuvant chemo(radio)therapy fol-
lowed by surgery is the main treatment option. Patients
with a histology other than adenocarcinoma or SCC and
metastatic disease at the time of operation were excluded.
Treatment
Multiple neoadjuvant regimens were employed in the
present study, determined by the standard of care and
recruiting clinical trials at the time of treatment (Table 1),
with patients treated earlier in the time period having
unimodality surgery. The majority of patients treated
received neoadjuvant chemotherapy. Transthoracic
esophagectomy with two-field lymph node dissection was
performed within 4–8 weeks after completion of the
neoadjuvant therapy using a conventional or minimally
invasive approach as previously described.13
Pathology and Staging
Histopathological reporting was carried out by specialist
gastrointestinal pathologists using a standardized proforma.
This was in line with guidelines produced by the Royal
College of Pathologists, which included tumor type and
differentiation, depth of tumor infiltration, and tumor
regression.14 The total number of nodes from each location,
as well as nodal metastases, were recorded, along with the
presence of extracapsular, lymphatic, and venous and
perineural invasion. Lymph nodes were dissected from the
specimen by the operating surgeon and analyzed separately
by the pathologist.15 The pathological stage was deter-
mined using the American Joint Committee on Cancer
(AJCC) 8th edition TNM staging system.16
Definition of Anastomotic Leak
AL was defined as a full-thickness gastrointestinal
defect involving the esophagus, anastomosis, staple line, or
conduit irrespective of presentation or method of identifi-
cation according to the ECCG criteria. Type I AL was
defined as a local defect requiring no change in therapy, or
treated medically or with dietary modification; type II AL
was defined as a localized defect requiring interventional
but not surgical therapy, for example interventional radi-
ology drain, stent or bedside opening, and packing of
incision; and type III AL was defined as a localized defect
requiring surgical therapy. In this study, patients with AL
associated with grade III–V complications, as defined by
the Clavien–Dindo 17 grading system, were defined as
severe esophageal AL (SEAL), and those with less severe
complications (Clavien–Dindo grade I/II were classified as
non-severe leaks [NSLs]). Postoperative contrast swallows
were not routinely used to determine if a leak was present
and investigations were performed if there was clinical
concern.
Follow-Up and Definition of Recurrence
Patients were followed up until death or for 10 years.
Patients were seen at 3- to 6-monthly intervals in the first
2 years, 6-monthly for 2 years, and then annually. Recur-
rence of disease was based on clinical grounds and was
confirmed endoscopically or radiologically. The minimum
follow-up was 30 months.
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TABLE 1 Clinicopathologic characteristics of patients undergoing esophagectomy for esophageal cancer
Overall [n =1063] No AL [n =976] AL [n =48] SEAL [n =39] p value
Age at presentation, years 65 (58–71) 65 (58–71) 64 (60–71) 66 (60–72) 0.700
Sex, male 811 (76) 739 (76) 41 (85) 31 (79) 0.271
Histology, SCC 207 (19) 190 (19) 12 (25) 5 (13) 0.361
BMI, kg/m2 26 (24–29) 26 (24–29) 27 (23–30) 26 (24–29) 0.777
Smoking status 0.302
Current 260 (24) 233 (24) 17 (35) 10 (26)
Ex-smoker 493 (46) 449 (46) 23 (48) 21 (54)
Never 302 (28) 286 (29) 8 (17) 8 (21)
Unknown 8 (1) 8 (1) 0 (0) 0 (0)
Alcohol status 0.009
Current 770 (72) 703 (72) 34 (71) 33 (85)
Ex-drinker 75 (7) 63 (6) 9 (19) 3 (8)
Never 199 (19) 191 (20) 5 (10) 3 (8)
Unknown 19 (2) 19 (2) 0 (0) 0 (0)
ASA grade 0.309
1 158 (15) 145 (15) 9 (19) 4 (10)
2 539 (51) 496 (51) 19 (40) 24 (62)
3 270 (25) 247 (25) 16 (33) 7 (18)
4 7 (1) 5 (1) 1 (2) 1 (3)
Unknown 89 (8) 83 (9) 3 (6) 3 (8)
Overall treatment, surgery only 500 (47) 458 (47) 17 (35) 25 (64) 0.028
Neoadjuvant chemotherapy regimen 0.035
CF 208 (20) 184 (19) 17 (35) 7 (18)
CROSS 20 (2) 18 (2) 2 (4) 0 (0)
ECF/ECX 285 (27) 267 (27) 11 (23) 7 (18)
None 500 (47) 458 (47) 17 (35) 25 (64)
Unknown 50 (5) 49 (5) 1 (2) 0 (0)
Overall AJCC 8th edition pathological stage 0.311
0 49 (5) 45 (5) 3 (6) 1 (3)
I 243 (23) 223 (23) 8 (17) 12 (31)
II 234 (22) 209 (21) 12 (25) 13 (33)
III 450 (42) 415 (43) 23 (48) 12 (31)
IV 87 (8) 84 (9) 2 (4) 1 (3)
Tumor grade 0.222
Well 94 (9) 87 (9) 2 (4) 5 (13)
Moderate 512 (48) 475 (49) 18 (38) 19 (49)
Poor 393 (37) 353 (36) 26 (54) 14 (36)
Unknown 64 (6) 61 (6) 2 (4) 1 (3)
Lymph nodes harvested 30 (23–39) 30 (23–39) 30 (22–39) 26 (20–37) 0.335
Margin status, R1 26 (2) 23 (2) 1 (2) 2 (5) 0.539
Lymphatic involvement 490 (46) 452 (46) 24 (50) 14 (36) 0.378
Venous involvement 373 (35) 347 (36) 19 (40) 7 (18) 0.062
Perineural involvement 476 (45) 442 (45) 23 (48) 11 (28) 0.099
Tumor regression grade 0.502
1 38 (4) 35 (4) 2 (4) 1 (3)
2 30 (3) 29 (3) 1 (2) 0 (0)
3 79 (7) 72 (7) 5 (10) 2 (5)
4 163 (15) 151 (15) 10 (21) 2 (5)
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Statistical Analysis
Categorical variables were compared using the Chi-
square test; non-normally distributed data were analyzed
using the Mann–Whitney U test; survival was estimated
using Kaplan–Meier survival curves and compared using
the log-rank test; and multivariable analyses used Cox
proportional hazards models. A subset analysis in patients
receiving neoadjuvant therapy prior to esophagectomy
were analyzed. A p value\ 0.05 was considered to be
statistically significant. Data analysis was performed using
R Foundation Statistical software (R 3.2.2) with TableOne,
ggplot2, Hmisc, Matchit and survival packages (R Foun-




Baseline Demographics This study included 1063
patients undergoing esophagectomy for esophageal
cancer, of whom 563 (53%) received neoadjuvant
therapy. Clinicopathological variables are presented in
Table 1. The median age of the entire cohort was 65 years
(interquartile range 58–71 years), 76% were male, and
19% had SCC. Of the 1063 patients, 8% developed ALs
(87/1063), of whom 45% (39/87) developed SEAL. Two
patients who developed AL (2%) died.
Across the groups, there were no significant differences
in age, sex, and rates of SCC; however, those developing
SEAL were more likely to receive unimodality surgery
(64%) compared with those with no ALs (47%) or NSL
only (35%) [p = 0.028]. There were no significant differ-
ences in the rates of advanced tumor stage, number of
lymph nodes examined, and R1 margins.
Postoperative Outcomes Patients developing SEAL had
a significantly longer length of stay in critical care (median
8 vs. 3 vs. 2 days; p\ 0.001) and overall hospital stay
(median 43 vs. 27 vs. 15 days; p\ 0.001) compared with
NSL or no AL. However, there were no significant
differences in the rates of surgical site infections, cardiac
complications, pulmonary complications, and in-hospital
mortality across these groups.
Overall and Recurrence-Free Survival There was no
significant difference in OS between the groups, with
patients experiencing SEAL having a median survival of
61 months, compared with 55 months for patients with
NSL and 41 months for patients with no AL only (p = 0.8)
(Fig. 1a). On Cox multivariate regression, both NSL only
(hazard ratio [HR] 0.91; p = 0.6) and SEAL (HR 1.24;
p = 0.3) were not independently associated with OS
(Table 2). Patients developing SEAL had similar RFS as
patients with NSL or no AL (Fig. 1b). On Cox multivariate
regression, NSL (HR 0.86; p = 0.5) or SEAL (HR 1.19;
p = 0.6) was not independently associated with OS
(Table 2).
Neoadjuvant and Surgery
Baseline Demographics In this subgroup analysis, 563
patients were included. Clinicopathological variables are
TABLE 1 continued
Overall [n =1063] No AL [n =976] AL [n =48] SEAL [n =39] p value
5 44 (4) 40 (4) 3 (6) 1 (3)
Unknown 709 (67) 649 (66) 27 (56) 33 (85)
Extracapsular spread 179 (17) 162 (17) 10 (21) 7 (18) 0.733
Critical care stay, days 2 (1–5) 2 (1–5) 3 (2–8) 8 (3–18) \ 0.001
Total hospital stay, days 15 (12–22) 15 (12–21) 27 (15–40) 43 (32–64) \ 0.001
Overall complications 709 (67) 622 (64) 48 (100) 39 (100) \ 0.001
Surgical site infection 108 (10) 100 (10) 4 (8) 4 (10) 0.912
Pulmonary complications 123 (12) 109 (11) 9 (19) 5 (13) 0.268
Cardiac complications 73 (7) 65 (7) 5 (10) 3 (8) 0.591
Anastomotic leaks 87 (8) 0 (0) 48 (100) 39 (100)
In-hospital mortality 38 (4) 34 (3) 1 (2) 3 (8) 0.324
30-day mortality 28 (3) 26 (3) 0 (0) 2 (5) 0.325
AL anastomotic leaks, ASA American Society of Anesthesiologists, SEAL severe esophageal AL, SCC squamous cell carcinoma, BMI body mass
index, AJCC American Joint Committee on Cancer, CF Cisplatin and 5-Fluorouracil, CROSS Carboplatin, Paclitaxel and Radiotherapy, ECF
Epirubicin, Cisplatin, 5-Fluorouracil, ECX Epirubicin, Cisplatin, Capecitabine
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presented in Table 3. Of these patients, 8% developed ALs
(45/563), of whom 31% (14/45) developed SEAL. Across
the groups, there were no significant differences in age,
sex, and rates of SCC, and no significant differences in
rates of advanced tumor stage, number of lymph nodes
examined, and R1 margins.
Postoperative Outcomes Patients developing SEAL had
significantly longer length of stay in critical care (median 8
vs. 4 vs. 2 days; p\ 0.001) and overall hospital stay
(median 37 vs. 27 vs. 14 days; p\ 0.001) compared with
NSL or no AL. However, there were no significant
differences in the rates of surgical site infections, cardiac
complications, pulmonary complications, and in-hospital
mortality across these groups.
Overall and Recurrence-Free Survival There was no
significant difference in survival between cohorts (SEAL:
median, not reported [NR] vs. NSL: 77 vs. no leak:
41 months; p = 0.058). On Cox multivariate regression,
A B
C D
FIG. 1 Impact of SEAL on OS and RFS in all patients and
neoadjuvant therapy and surgery only. a OS in all patients; b RFS
in all patients; c OS in NAT and surgery and d RFS in NAT and
surgery. AL anastomotic leak, NR not reached, NSL non-severe leak,
SEAL severe esophageal AL, OS overall survival, RFS recurrence-free
survival
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both NSL (HR 0.65; p = 0.1) and SEAL (HR 0.48;
p = 0.09) were not independently associated with OS
(Table 4). Patients developing SEAL had similar RFS as
patients with NSL or no AL (Fig. 1d). On Cox multivariate
regression, both NSL (HR 0.70; p = 0.3) or SEAL (HR
1.04; p = 0.9) were not independently associated with OS
(Table 4).
TABLE 2 Cox multivariate
regression on the impact of
SEAL on overall survival and
recurrence-free survival
Overall survival Recurrence-free survival
HR (95% CI) p value HR (95% CI) p value
Age at presentation 1.02 (1.01–1.03) \ 0.001 1.00 (0.99–1.01) 0.991
Gender, male 1.34 (1.10–1.64) 0.003 1.39 (1.07–1.80) 0.015
ASA grade
1 Ref Ref
2 1.17 (0.93–1.48) 0.189 0.89 (0.67–1.19) 0.442
3 1.30 (1.01–1.68) 0.041 0.99 (0.72–1.35) 0.93
4 1.96 (0.83–4.60) 0.124 0.37 (0.05–2.77) 0.335
Unknown 1.11 (0.81–1.54) 0.515 1.08 (0.72–1.62) 0.722
Histology, SCC 1.30 (1.04–1.61) 0.019 1.10 (0.82–1.48) 0.522
Operation year 0.96 (0.94–0.98) 0.001 0.97 (0.94–1.00) 0.038
Overall treatment, surgery only 1.14 (0.93–1.41) 0.213 1.12 (0.85–1.47) 0.419
Tumor grade
Well Ref Ref
Moderate 1.28 (0.92–1.78) 0.141 2.22 (1.21–4.08) 0.01
Poor 1.55 (1.09–2.19) 0.014 2.62 (1.41–4.87) 0.002
Unknown 1.73 (1.01–2.97) 0.046 2.70 (1.06–6.90) 0.038
Margin status, R1 2.05 (1.35–3.11) 0.001 1.72 (0.97–3.04) 0.065
Lymphatic involvement, yes 1.40 (1.15–1.71) 0.001 1.58 (1.23–2.04) \ 0.001
Venous involvement, yes 1.00 (0.83–1.22) 0.971 1.07 (0.84–1.36) 0.59
Perineural involvement, yes 1.42 (1.17–1.72) \ 0.001 1.57 (1.23–2.00) \ 0.001
Tumor regression grade
1 Ref Ref
2 1.14 (0.48–2.71) 0.763 0.96 (0.32–2.85) 0.941
3 0.94 (0.45–1.95) 0.871 0.74 (0.30–1.83) 0.52
4 1.28 (0.66–2.49) 0.469 1.02 (0.44–2.35) 0.963
5 1.35 (0.65–2.79) 0.42 0.99 (0.40–2.47) 0.984
Unknown 1.25 (0.66–2.36) 0.498 0.82 (0.36–1.83) 0.625
Extracapsular spread, yes 1.71 (1.34–2.18) \ 0.001 1.42 (1.06–1.91) 0.02
Overall AJCC 8th edition pathological stage
0 Ref Ref
I 1.09 (0.59–2.00) 0.788 1.94 (0.58–6.41) 0.279
II 1.09 (0.59–2.00) 0.781 2.28 (0.70–7.45) 0.172
III 2.40 (1.31–4.40) 0.005 5.93 (1.82–19.28) 0.003
IV 3.57 (1.85–6.88) \ 0.001 7.77 (2.30–26.25) 0.001
Anastomotic leaks
No anastomotic leaks Ref Ref
NSL 0.91 (0.62–1.35) 0.646 0.86 (0.52–1.40) 0.539
SEAL 1.24 (0.82–1.88) 0.302 1.19 (0.66–2.16) 0.561
ASA American Society of Anesthesiologists, SEAL severe esophageal anastomotic leak, SCC squamous cell
carcinoma, AJCC American Joint Committee on Cancer, HR hazard ratio, CI confidence interval, Ref
reference, NSL non-severe leak
Bold values indicate statistical significance (P\0.05)
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TABLE 3 Clinicopathologic characteristics of patients undergoing esophagectomy following neoadjuvant therapy for esophageal cancer
No AL [n =518] AL [n =31] SEAL [n =14] p value
Age at presentation, years 64 (57–69) 63 (60–70) 66 (60–73) 0.581
Sex, male 407 (79) 26 (84) 13 (93) 0.346
Histology, SCC 101 (19) 10 (32) 1 (7) 0.108
BMI, kg/m2 26 (24–30) 28 (25–30) 26 (24–29) 0.702
Smoking status 0.169
Current 121 (23) 14 (45) 4 (29)
Ex-smoker 246 (47) 11 (35) 8 (57)
Never 146 (28) 6 (19) 2 (14)
Unknown 5 (1) 0 (0) 0 (0)
Alcohol status 0.274
Current 391 (75) 24 (77) 12 (86)
Ex-drinker 31 (6) 4 (13) 2 (14)
Never 92 (18) 3 (10) 0 (0)
Unknown 4 (1) 0 (0) 0 (0)
ASA grade 0.644
1 74 (14) 6 (19) 1 (7)
2 292 (56) 12 (39) 9 (64)
3 124 (24) 12 (39) 3 (21)
4 2 (0) 0 (0) 0 (0)
Unknown 26 (5) 1 (3) 1 (7)
Neoadjuvant chemotherapy regimen 0.179
CF 184 (36) 17 (55) 7 (50)
CROSS 18 (3) 2 (6) 0 (0)
ECF/ECX 267 (52) 11 (35) 7 (50)
Unknown 49 (9) 1 (3) 0 (0)
Overall AJCC 8th edition pathological stage 0.683
0 30 (6) 2 (6) 1 (7)
I 64 (12) 4 (13) 1 (7)
II 135 (26) 8 (26) 7 (50)
III 233 (45) 15 (48) 5 (36)
IV 56 (11) 2 (6) 0 (0)
Tumor grade 0.768
Well 17 (3) 1 (3) 1 (7)
Moderate 251 (48) 12 (39) 6 (43)
Poor 212 (41) 17 (55) 6 (43)
Unknown 38 (7) 1 (3) 1 (7)
Lymph nodes harvested 33 (26–42) 34 (26–40) 36 (30–39) 0.974
Margin status, R1 6 (1) 0 (0) 0 (0) 0.768
Lymphatic involvement 259 (50) 15 (48) 6 (43) 0.86
Venous involvement 190 (37) 11 (35) 2 (14) 0.227
Perineural involvement 245 (47) 14 (45) 5 (36) 0.679
Tumor regression grade 0.822
1 21 (4) 2 (6) 0 (0)
2 28 (5) 1 (3) 0 (0)
3 72 (14) 5 (16) 2 (14)
4 148 (29) 10 (32) 2 (14)
5 38 (7) 3 (10) 1 (7)
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DISCUSSION
The results of this study indicate that patients with AL,
as well as those with severe ALs, do not have a poorer
long-term survival than those patients who do not have an
AL. In the short-term, NSL and SEAL were associated
with a significantly longer stay in critical care and also
longer time in hospital postoperatively. In-hospital mor-
tality was not significantly different between those who had
an AL and those who did not. In addition, there were
comparable oncological outcomes between the groups in
terms of R1 margin rates and number of lymph nodes
harvested, which may reflect the similar survival between
the groups, even after multivariable Cox regression
analyses.
These findings are contrary to those of a previously pub-
lished multicenter study that demonstrated that SEAL is
associated with reduced long-term OS and worse recurrence
rates.9 However, the previous study had several limitations
that are imperative to understanding the impact of AL on
survival. First, multicenter data are often heterogenous in
regard to the type of surgery performed, which in this case
included transhiatal and three-stage procedures that are
established to have different survival profiles. In contrast, the
present study focused only on patients who had undergone a
two-stage transthoracic esophagectomy. Second, the previ-
ous multicenter study is limited by center variation in the
context of volume, pathological assessment of specimens,
and multidisciplinary pathways.9 Interestingly, center vol-
ume was associated with SEAL, which may also reflect the
poor long-term survival outcomes. In addition, multicenter
studies such as this, as well as other smaller studies, make it
difficult to adjust for 30- and 90-day mortality. In the present
study, all patients went through the same standardized
multidisciplinary team process and were treated in a high-
volume unit. There has been an increasing trend for
esophagectomies to be carried out at high-volume units as
this has been proven to improve both short- and long-term
outcomes.20–22
The mechanism by which AL contributes towards
poorer long-term survival is unclear. It has been postulated
and extrapolated from colorectal surgery studies that can-
cer cells may be shed into the gut lumen during surgery,23
and thus anastomotic leakage allows these to spread into
the mediastinum, contributing to local recurrence.9 There is
conflicting evidence regarding whether perioperative mor-
bidity impacts on long-term survival. While several studies
have indicated that complications have no impact on sur-
vival,24,25 data from a Swedish national database suggested
that surgical complications may be a poor predictor of
long-term survival,26 and further studies from Japan have
implicated pulmonary infections as having an unfavorable
prognosis in patients who received neoadjuvant
chemotherapy.10,27,28
In the present study, patients underwent a standardized
two-field transthoracic esophagectomy, which has been
previously described. Median lymph node yield was high
and R1 resection rates low, both of which have been shown
to contribute towards improved OS.29,30 There appears to
be no difference in the impact of AL, irrespective of
whether or not a patient received neoadjuvant treatment.
However, it may be that in the era of neoadjuvant treat-
ment, the long-term oncological impact of an AL is
lessened by this treatment.
TABLE 3 continued
No AL [n =518] AL [n =31] SEAL [n =14] p value
Unknown 211 (41) 10 (32) 9 (64)
Extracapsular spread 127 (25) 9 (29) 4 (29) 0.809
Critical care stay, days 2 (1–4) 4 (2–8) 8 (2–16) 0.001
Total hospital stay, days 14 (11–19) 27 (16–40) 37 (31–60) \ 0.001
Overall complications 316 (61) 31 (100) 14 (100) \ 0.001
Surgical site infection 45 (9) 2 (6) 3 (21) 0.226
Pulmonary complications 69 (13) 6 (19) 2 (14) 0.636
Cardiac complications 48 (9) 5 (16) 1 (7) 0.43
Anastomotic leaks 0 (0) 31 (100) 14 (100) \ 0.001
In-hospital mortality 15 (3) 0 (0) 0 (0) 0.512
30-day mortality 10 (2) 0 (0) 0 (0) 0.643
AL anastomotic leak, ASA American Society of Anesthesiologists, HR hazard ratio, SEAL severe esophageal AL, SCC squamous cell carcinoma,
BMI body mass index, AJCC American Joint Committee on Cancer, CF Cisplatin and 5-Fluorouracil, CROSS Carboplatin, Paclitaxel and
Radiotherapy, ECF Epirubicin, Cisplatin, 5-Fluorouracil, ECX Epirubicin, Cisplatin, Capecitabine
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While it could be argued that one of the weaknesses of
this study is that all the data come from a single unit, this is
also one of its strengths as it provides evidence of potential
outcomes for patients when looked after at an experienced
center with a high volume of patients. The overall AL rate
of 8% is comparable with other studies.4,10,15,26–29 For
those patients who developed a leak, the mortality rate was
low (2%) and this translates to a 0.2% chance of dying
from an AL after esophagectomy. While it is clear that AL
TABLE 4 Cox multivariate
regression on the impact of
SEAL on overall survival and
recurrence-free survival
Overall survival Recurrence-free survival
HR (95% CI) p value HR (95% CI) p value
Age at presentation 1.01 (1.00–1.02) 0.118 1.00 (0.98–1.01) 0.753
Gender, male 1.41 (1.04–1.92) 0.027 1.21 (0.84–1.73) 0.306
ASA grade
1 Ref Ref
2 0.95 (0.69–1.32) 0.77 0.90 (0.61–1.32) 0.581
3 1.00 (0.69–1.44) 0.987 0.95 (0.61–1.47) 0.821
4 0.95 (0.21–4.37) 0.952 0.53 (0.07–4.35) 0.557
Unknown 0.80 (0.45–1.42) 0.448 0.82 (0.41–1.64) 0.578
Histology, SCC 1.26 (0.91–1.75) 0.162 1.00 (0.66–1.51) 0.987
Operation year 0.97 (0.92–1.02) 0.19 0.96 (0.91–1.02) 0.206
Tumor grade
Well Ref Ref
Moderate 1.35 (0.68–2.68) 0.392 1.19 (0.54–2.59) 0.668
Poor 1.68 (0.84–3.36) 0.145 1.35 (0.61–2.98) 0.459
Unknown 1.09 (0.39–3.09) 0.868 1.10 (0.30–4.05) 0.887
Margin status, R1 1.33 (0.57–3.15) 0.511 1.73 (0.61–4.89) 0.303
Lymphatic involvement, yes 1.36 (1.02–1.80) 0.034 1.24 (0.88–1.73) 0.212
Venous involvement, yes 1.00 (0.76–1.31) 0.999 1.06 (0.77–1.47) 0.708
Perineural involvement, yes 1.51 (1.15–1.97) 0.003 1.81 (1.30–2.51) \ 0.001
Tumor regression grade
1 Ref Ref
2 0.94 (0.26–3.45) 0.93 0.23 (0.05–1.13) 0.07
3 0.84 (0.26–2.76) 0.779 0.30 (0.08–1.21) 0.09
4 1.21 (0.38–3.78) 0.748 0.44 (0.12–1.69) 0.235
5 1.33 (0.41–4.35) 0.637 0.45 (0.11–1.79) 0.255
Unknown 1.11 (0.35–3.53) 0.863 0.32 (0.08–1.23) 0.097
Extracapsular spread, yes 1.70 (1.26–2.28) \ 0.001 1.40 (0.99–1.99) 0.057
Overall AJCC 8th edition pathological stage
0 Ref Ref
I 0.74 (0.27–2.08) 0.572 3.98 (0.76–20.94) 0.103
II 0.55 (0.21–1.46) 0.23 2.51 (0.51–12.38) 0.259
III 1.43 (0.53–3.85) 0.474 7.01 (1.37–35.80) 0.019
IV 1.74 (0.61–4.98) 0.301 7.98 (1.49–42.91) 0.015
Anastomotic leaks
No anastomotic leaks Ref Ref
NSL 0.65 (0.39–1.09) 0.105 0.70 (0.38–1.30) 0.259
SEAL 0.48 (0.21–1.12) 0.09 1.04 (0.45–2.43) 0.919
ASA American Society of Anesthesiologists, HR hazard ratio, CI confidence interval, NSL non-severe leak,
Ref reference, SEAL severe esophageal anastomotic leak, SCC squamous cell carcinoma, AJCC American
Joint Committee on Cancer
Bold values indicate statistical significance (P\0.05)
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is likely to prolong both critical care stay and the total time
spent in hospital, an aggressive conservative management
strategy can provide excellent outcomes.2
CONCLUSION
The present study refutes the suggestion that AL leads to
poorer long-term oncological outcomes. A standardized
esophagectomy with careful consideration for oncological
principles and management of complications at a high-
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